Browse News
Filter News
Found 305 articles
-
MyOme Secures $23M in Series B Funding to Deliver Clinical Whole Genome Insights to Help Families Manage Risk for Inherited Diseases
6/21/2022
MyOme, a clinical whole genome platform analysis company, announced that the company has raised $23 million in an oversubscribed series B financing round led by Healthcare Venture Partners, bringing the total raised to over $36M.
-
Quantum-Si Appoints Vikram Bajaj, Ph.D., to Board of Directors
6/16/2022
Quantum-Si Incorporated announced the appointment of Vikram Bajaj, Ph.D., co-founder and former Chief Scientific Officer of Verily, to its Board of Directors.
-
Recent funding saw support for a platform that selectively degrades DNA, software to help read mammograms and a company using corn genetics to develop cancer-targeting viruses.
-
Mirvie Raises $60 Million Funding Round to Shape the Future of Pregnancy Health
5/17/2022
Mirvie, a pioneer in predicting unexpected pregnancy complications, announced it has raised a total of $90 million to date following the close of its Series B funding.
-
Remix Therapeutics Closes $70 Million Series B Financing
5/17/2022
Remix Therapeutics, a biotechnology company developing small molecule therapies designed to reprogram RNA processing and address the underlying drivers of disease, announced the close of a $70 million Series B financing.
-
Kriya Therapeutics secured $270 million that will be used to advance its fully integrated gene therapy pipeline and expand engineering, manufacturing and computation.
-
Kriya Announces $270 Million Series C Financing to Advance Fully Integrated Gene Therapy Engine
5/16/2022
Kriya Therapeutics, Inc., a fully integrated gene therapy company pioneering novel technologies and therapeutics, announced a $270 Million Series C financing.
-
Pardes Biosciences Reports Full Year 2021 Financial Results and Provides Business Update
3/29/2022
Pardes Biosciences, Inc. (NASDAQ: PRDS), today reported financial results for the full year ended December 31, 2021 and provided a business update.
-
Mammoth Biosciences Announces Key Leadership Appointments
3/23/2022
Mammoth Biosciences, a biotech company building the next generation of CRISPR products to cure and detect disease, today announced the appointment of Elaine Sun as Chief Operating Officer (COO) and Chief Financial Officer (CFO).
-
Cognito Therapeutics and Aetion Announce Partnership to Use Artificial Intelligence to Identify Rapidly Progressing Forms of Mild Cognitive Impairment and Alzheimer's Disease
3/8/2022
Cognito Therapeutics and Aetion announced a strategic partnership to develop a validated predictive model to identify patients with rapidly progressing mild cognitive impairment and Alzheimer’s disease.
-
DNAnexus Secures $200 Million Funding Led by Blackstone Growth to Advance its Biomedical Data-Driven Technology Platform for Precision Medicine
3/8/2022
DNAnexus, Inc., a leading provider of cloud-based biomedical data analysis software serving the life sciences community, today announced a $200 million financing round to accelerate the global adoption of its technology, translating the world’s complex multi-omics and clinical data into tangible insights and personalized treatments.
-
Foresite Labs CEO Vikram Bajaj believes that data science will fundamentally transform the life sciences and translate into the development of new therapeutics for various disease states.
-
Koneksa Raises $45M Series C Financing to Accelerate Expansion of Digital Biomarker Platform
2/7/2022
Koneksa announced today the completion of a $45M Series C financing round, led by AyurMaya, an affiliated fund of Matrix Capital Management, with participation from Takeda Ventures and Velosity Capital.
-
TenSixteen Bio launched Thursday with a $40 million Series A financing round funded by Foresite Capital and GV, formerly Google Ventures.
-
Mammoth Biosciences Receives FDA Emergency Use Authorization for First CRISPR-based High-Throughput COVID-19 Test
1/24/2022
Mammoth Biosciences, Inc. , today announced that the U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for its DETECTR BOOST ® SARS-CoV-2 Reagent Kit, a first of its kind high-throughput solution that combines the power of CRISPR with laboratory automation for SARS-CoV-2 testing.
-
ImmPACT Bio provided an optimistic update on a Phase I clinical study evaluating its CD19-CD20 bi-specific Chimeric Antigen Receptor T-cell (CAR-T) therapy.
-
Such a deep, data-driven approach is enabling precision medicine, in particular, which is expanding from oncology to autoimmune diseases and other conditions.
-
ImmPACT Bio Closes $111 Million Series B Financing, Names New Board Chair and New President and CEO, and Updates on Phase 1 Clinical Study in Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
1/20/2022
ImmPACT Bio USA, Inc., a clinical-stage company developing transformative logic-gate based chimeric antigen receptor T-cell therapies for treating cancer, announced it has closed $111 million in Series B financing, led by venBio Partners along with co-leads Foresite Capital and Decheng Capital.
-
Pardes is funneling the funds into financing the next stage of clinical trials and commercial production of its lead oral antiviral drug, PBI-0451, for the treatment and prevention of SARS-CoV-2 infections.
-
Maze Therapeutics Announces $190 Million Financing to Support the Advancement of Nine Precision Medicine Programs and Compass Platform for Genetically Defined Diseases
1/10/2022
Maze Therapeutics today announced a $190 million financing led by Matrix Capital Management.